Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott Laboratories ABT, -2.51% said late Thursday it is voluntarily recalling powder baby formulas, including its best-selling Similac, made in one plant in Michigan after it received four consumer complaints related to the bacteria Cronobacter sakazakii or Salmonella Newport in infants who had consumed powder infant formula made in the factory. "During testing in our Sturgis, Mich.

Abbott recalls some Similac, other powder baby formulas due to Salmonella, Cronobacter complaints

ABBOTT PARK, Ill., Feb. 17, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) is initiating a proactive, voluntary recall of powder formulas, including Similac, Alimentum and EleCare manufactured in Sturgis, Mich.

Abbott Voluntarily Recalls Powder Formulas Manufactured at One Plant

This longtime winner still has bright prospects ahead of it.

2 Green Flags for Abbott Laboratories' Future

Amgen

Baxter

Cerner

Quest Diagnostics

Eli Lilly

Merck

Pfizer

Stryker

UnitedHealth Group

If any investor has stood the test of time, it is Warren Buffett, and with good reason.

10 Health Care Stocks Warren Buffett Owns That Offer Safety and Dependable Dividends

Abbott may soon be returning to its pre-pandemic days.

Why This Healthcare Giant Expects Decreased Covid Profits in 2022

Alnylam Pharmaceuticals

Bristol-Myers

Regeneron Pharmaceuticals

Waters

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.

The Vanguard Health Care Fund's Top 5 Trades

ABM Industries

Lowe's

Nordson

PPG Industries

Stanley Black & Decker

Sysco

The 36 Dividend Kings started 2022 on a sour note losing 3.88% during January. The 8 best dividend kings based on forecasted growth and valuation trailed the average dividend king return by 129 bps in January.

My Best Dividend Kings For February 2022

ABBOTT PARK, Ill., Feb. 7, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the world's first patient implants of a dual-chamber leadless pacemaker system as part of its AVEIR DR i2i™ pivotal clinical study.

Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial

Diversified global medical science products maker Abbott (NYSE: ABT) stock has sold off with the benchmark indexes in a throw the baby out with the bath water type reaction.

Abbott Stock is an Oversold Play

Colgate-Palmolive

Essex Property Trust

PepsiCo

Atmos Energy

It was nice while it lasted, but the dumpster fire that was the quarterly earnings report from Meta Platforms (known for years as Facebook) may have lit the fuse for a continuation of the selling we saw almost the entire month of January.

The Coming Sell-Off May Be Huge: 5 Dividend Aristocrats to Buy Now for Safety and Income

BioNTech SE

Fulgent Genetics

Moderna

Novavax

6 Stocks That Could Soar If New Coronavirus Variants Emerge

Even though COVID-19 case rates are surging in the United States and other geographies, Abbott is seeing growth in its consumer-facing businesses like nutrition, EPD and diabetes care.

Abbott's (ABT) Diabetes Arm Booms, Neuromodulation Sales Soft

Medtronic

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the fourth quarter of 2021 earlier this week.

Eaton Vance Worldwide Health Sciences Fund Dumps Medtronic, Boosts Abbott Labs

Align Technology

Anthem

DaVita

Thermo Fisher Scientific

Should investors be paying more attention to these health care stocks?

5 Top Health Care Stocks To Watch Before February 2022

On Wednesday, Abbott Laboratories ( ABT , Financial) reported its earnings results for the fourth quarter and full year of 2021.

Abbott Lab's Sales Jump 24.5% in 2021

Abbott Lab's Sales Jumped 24.5% in 2021

As has become the theme of 1st quarter trading, it looks like institutional activity capped the gains in Abbot Laboratories (NYSE: ABT) but the bottom may already be in sight for shareholders. While the institutional activity shifted in favor of the bears in the 3rd and 4th quarters of 2021 the tide seems to be turning again.

Institutions Cap Gains In Abbot Laboratories

Abbot Laboratories (ABT) announced better-than-expected fourth-quarter earnings results ahead of the open today.

Annual Forecast Weighs On Healthcare Name

Abbott management, known for under promising and over delivering, will do better than Wall Street thinks.

Cramer's Investing Club: We believe the market is wrong on core holding Abbott's future potential

Ford Motor Company

Abbott Laboratories (ABT) CEO Robert Ford on Q4 2021 Results - Earnings Call Transcript

Abbott's (ABT) COVID-19 testing-related sales in Q4 increased on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.

Abbott's (ABT) Q4 Earnings and Revenues Beat Estimates

Abbott (ABT) delivered earnings and revenue surprises of 11.86% and 8.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) Q4 Earnings and Revenues Surpass Estimates

Shares of the maker of a leading Covid-19 at-home antigen test were down slightly in premarket trading Wednesday.

Abbott Beats Earnings Expectations. The Stock is Down.

Abbott Laboratories (NYSE: ABT) has reported Q4 FY21 adjusted EPS of $1.32, down from $1.45 a year ago but better than the consensus of $1.21. Q4 sales of $11.5 billion increased 7.2% on a reported basis and 7.7% on an organic basis, beating the consensus of $10.71 billion.

Abbott Posts $2.3B In COVID-19 Test Sales In Q4; Issues FY22 Outlook

Shares of Abbott Laboratories ABT, -0.44% were down 0.8% in premarket trading on Wednesday. The company beat expectations for both earnings and revenue in the fourth quarter, bolstered by more than $2 billion in sales of its COVID-19 tests during the quarter's omicron surge.

News for Abbott Labs Stock (ABT)